Core - Biomarker Development Laboratory (BDL)

作为生物标志物表征中心的一部分，生物标志物开发实验室 将开发改进的方法来检测DNA甲基化变化，以便早期发现 肺癌的症状由James赫尔曼博士和Tza-Huei Jeff Wang博士领导的多学科 一组研究人员将开发出改进的DNA甲基化改变小组， 检测血浆中循环肿瘤DNA（ctDNA）的变化，以确定肿瘤的起源。 肺癌或其他常见恶性肿瘤的ctDNA，并继续改善 在甲基化检测方法中，以更好地检测存在于细胞中的少量ctDNA， 等离子体该EDRN生物标志物开发实验室将使用高质量， 前瞻性收集生物标本，以开发高度敏感，特异性和 用于检测肿瘤特异性DNA甲基化的定量方法 血浆异常。这些方法将转移至生物标志物参考 实验室将在CLIA环境中进行标准化和性能测试。

As part of a Biomarker Characterization Center, the Biomarker Development Laboratory will develop improved methods to detect DNA methylation changes for the early detection of lung cancer. Led by Dr. James Herman and Dr. Tza-Huei Jeff Wang, a multidisciplinary team of investigators will develop improved panels of DNA methylation alterations able to detect circulating tumor DNA (ctDNA) changes in plasma, to determine the origin of ctDNA from lung cancer or other common malignancies, and to continue improvements in methylation detection methods to better detect the small amounts of ctDNA present in plasma. This EDRN Biomarker Development Laboratory will use high quality, prospectively collected biospecimens to develop highly sensitive, specific and quantitative approaches for the detection of tumor-specific DNA methylation abnormalities in plasma. These methods will be transferred to the Biomarker Reference Laboratory to be standardized and tested for performance in a CLIA setting.